Kromek Group (KMK) CMD 2025 summary

Strategic Overview and Growth Pillars

• Two core business segments: Advanced Imaging (AI) and CBRN Detection, each positioned as a growth pillar with high barriers to entry due to proprietary technology, IP, and deep customer relationships.

• Advanced Imaging leverages proprietary CZT technology for medical, security, and industrial applications, focusing on OEM components and targeting a $400M annual TAM, with sole supplier status for CZT technology.

• CBRN Detection targets a $1B+ annual TAM, offering end-user products for radiation and biological threats, with a distributed customer base including governments and critical infrastructure.

• Both divisions are supported by a strong innovation engine, skilled workforce, and agile culture, driving sustainable competitive advantage.

• Growth is driven by global trends: healthcare cost pressures, aging populations, geopolitical instability, and nuclear threats.

Financial Performance and Guidance

• FY2025 is transformational, with revenue projected above £26M (>30% growth) and a shift to positive PBT (>£1.8M), building on four consecutive years of revenue growth.

• Gross margin improved from 46.7% in FY22 to 55.2% in FY24.

• A $37.5M Siemens contract significantly strengthened the balance sheet, with $25M cash received and revenue recognized over four years.

• Divisional reporting introduced, with a roughly 50/50 revenue split between AI and CBRN, though FY25 is weighted toward Advanced Imaging due to a major enablement deal.

• Medium-term targets include >£60M revenue, c30% EBITDA margin, and c20% revenue CAGR, aiming to double EBITDA margins.

Market Opportunities and Business Models

• Advanced Imaging market driven by a technology shift to CZT, with SPECT and CT as major revenue drivers; SPECT market nearing full CZT adoption by 2030, and photon-counting CT market is 15x larger than SPECT.

• Significant contracts secured with Siemens Healthineers, Spectrum Dynamics, and a tier one OEM; revenue profile for the next 12–36 months driven by these enablement programs.

• CBRN Detection addresses a $1B+ TAM, with products for radiation and biological threat detection; revenue streams include product sales, service, R&D, and government contracts.

• Biological detection R&D, funded by agencies like DHS, aims to deliver real-time, miniaturized, and autonomous pathogen detection, with a razor-blade consumables model for future commercialization.

• Both divisions benefit from strong IP, high barriers to entry, and long-term customer relationships.